Yoneyama Kimiyasu, Nakagawa Motohito, Hara Asuka
Department of Breast Surgery, Hiratsuka City Hospital, 1-19-1 Minamihara, Hiratsuka-shi, Kanagawa 254-0065, Japan.
Int J Surg Case Rep. 2021 Apr;81:105788. doi: 10.1016/j.ijscr.2021.105788. Epub 2021 Mar 17.
Mutation-positive patients who develop unilateral breast cancer require different treatments, such as prophylactic mastectomy of the contralateral breast, from those used for other breast cancer patients. If a mutation is found before surgery, it is necessary to consider a surgical procedure that includes reconstruction. For BRCA mutation-positive patients, a suitable treatment must be selected. In Japan, a test for BRCA mutation has been covered by health insurance since 2020, making it possible to preoperatively test patients who are suspected of being positive. We report a case of simultaneous bilateral breast cancer that was found to be BRCA mutation-positive preoperatively and underwent bilateral subcutaneous mastectomy and breast reconstruction.
A 57-year-old woman was admitted to our hospital after a breast cancer screening revealed a mass in the left breast. She had a family history of breast cancer, including her sister, aunt, and cousin. She was suspected of being malignant with a mass on both sides of her breast on imaging. She underwent needle biopsy and was diagnosed as having bilateral invasive ductal carcinoma, for which she was placed on preoperative chemotherapy. Due to the strong family history of bilateral breast cancer, the patient was recommended to undergo a BRCA gene-mutation test and she consented. The result was positive for BRCA1 mutation. Although it was judged that bilateral breast-conserving surgery was sufficiently possible, bilateral subcutaneous mastectomy and breast reconstruction were performed based on BRCA mutation-positive status.
Performing a preoperative BRCA test may change the surgical procedure. BRCA tests are beneficial to patients, but the timing of the tests is important. Care must be taken not to force the patient.
Knowing whether the patient is BRCA mutation-positive is extremely important for selecting surgical procedures and treatment methods. BRCA testing should be recommended for patients who are strongly suspected of being positive, but the decision should be the patient's. It is therefore necessary to provide accurate information and engage in a dialogue with the patient, but the medical staff should not pressure the patient to have the test.
发生单侧乳腺癌的突变阳性患者需要与其他乳腺癌患者采用不同的治疗方法,例如对侧乳房预防性乳房切除术。如果在手术前发现突变,则有必要考虑包括重建在内的手术程序。对于BRCA突变阳性患者,必须选择合适的治疗方法。在日本,自2020年以来,BRCA突变检测已被纳入医疗保险范围,这使得术前对疑似阳性患者进行检测成为可能。我们报告一例术前发现为BRCA突变阳性的双侧同时性乳腺癌病例,并接受了双侧皮下乳房切除术和乳房重建术。
一名57岁女性在乳腺癌筛查发现左乳有肿块后入院。她有乳腺癌家族史,包括她的姐姐、阿姨和表妹。影像学检查显示她双侧乳房有肿块,怀疑为恶性。她接受了针吸活检,被诊断为双侧浸润性导管癌,并接受了术前化疗。由于有双侧乳腺癌的强烈家族史,建议该患者进行BRCA基因突变检测,她表示同意。检测结果显示BRCA1突变阳性。尽管判断双侧保乳手术是完全可行的,但基于BRCA突变阳性状态,还是进行了双侧皮下乳房切除术和乳房重建术。
进行术前BRCA检测可能会改变手术程序。BRCA检测对患者有益,但检测时机很重要。必须注意不要强迫患者。
了解患者是否为BRCA突变阳性对于选择手术程序和治疗方法极为重要。对于高度怀疑为阳性的患者应建议进行BRCA检测,但决定权应在患者手中。因此,有必要提供准确信息并与患者进行沟通,但医务人员不应向患者施压进行检测。